These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15539841)

  • 1. Comparative study of apoptotic antitumor effect between angiogenesis inhibitor AGM-1470 and MVAC chemotherapy on rat urinary bladder cancer.
    Sejima T; Isoyama T; Miyagawa I
    Urol Int; 2004; 73(3):226-33. PubMed ID: 15539841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
    Galsky MD; Pal SK; Chowdhury S; Harshman LC; Crabb SJ; Wong YN; Yu EY; Powles T; Moshier EL; Ladoire S; Hussain SA; Agarwal N; Vaishampayan UN; Recine F; Berthold D; Necchi A; Theodore C; Milowsky MI; Bellmunt J; Rosenberg JE;
    Cancer; 2015 Aug; 121(15):2586-93. PubMed ID: 25872978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer.
    Necchi A; Mariani L; Giannatempo P; Raggi D; Farè E; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Maffezzini M; Pizzocaro G; De Braud FG; Gianni AM; Salvioni R
    Clin Genitourin Cancer; 2014 Jun; 12(3):203-209.e1. PubMed ID: 24394493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Neoadjuvant chemotherapy in advanced-stage bladder carcinoma. A randomized prospective study comparing MVAC and MVEEC].
    Monica B; Larosa M; Frattini A; Macaluso G; Cocconi G; Passalacqua R; Leonardi F
    Arch Ital Urol Androl; 1994 Dec; 66(5):235-43. PubMed ID: 7812302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MVAC chemotherapy-induced apoptosis and p53 alterations in the rat model of bladder cancer.
    Zhang X; Jin L; Takenaka I
    Urology; 1998 Nov; 52(5):925-31. PubMed ID: 9801132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term effects of TNP-470 in combination with cisplatin in the rat model of bladder cancer.
    Zhang X; Yamashita M; Uetsuki H; Kakehi Y
    In Vivo; 2002; 16(5):293-7. PubMed ID: 12494866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin.
    van de Putte EE; Mertens LS; Meijer RP; van der Heijden MS; Bex A; van der Poel HG; Kerst JM; Bergman AM; Horenblas S; van Rhijn BW
    World J Urol; 2016 Feb; 34(2):157-62. PubMed ID: 26184106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
    Okuno SH; Mailliard JA; Suman VJ; Edmonson JH; Creagan ET; Nair S; Levitt R; Kugler JW
    Cancer; 2002 Apr; 94(8):2224-31. PubMed ID: 12001121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of tumor angiogenesis during cisplatin chemotherapy for bladder cancer improves treatment outcome.
    Kong C; Zhu Y; Sun C; Li Z; Sun Z; Zhang X; Takanaka I
    Urology; 2005 Feb; 65(2):395-9. PubMed ID: 15708074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective analysis of clinical outcomes with neoadjuvant cisplatin-based regimens for muscle-invasive bladder cancer.
    Pal SK; Ruel NH; Wilson TG; Yuh BE
    Clin Genitourin Cancer; 2012 Dec; 10(4):246-50. PubMed ID: 22981208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognosis in pT3b infiltrating tumors of the bladder treated by adjuvant chemotherapy].
    Sahwi A; Robert M; Delbos O; Legouffe E; Guiter J; Navratil H
    Prog Urol; 1998 Dec; 8(6):1007-11. PubMed ID: 9894259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
    Culine S; Fléchon A; Gravis G; Roubaud G; Loriot Y; Joly F; Barthélémy P; Assaf E; Mahammedi H; Beuzeboc P; Houédé N; Rolland F; Guillot A; Gross-Goupil M; Spano JP; Tartas S; Deblock M; Chevreau C; Serrate C; Manduzio H; Habibian M; Thézénas S; Allory Y
    Clin Genitourin Cancer; 2021 Aug; 19(4):e216-e222. PubMed ID: 33753043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Neoadjuvant chemotherapy with MVAC in bladder carcinoma: Is the feasibility really established? Of: Benadiba et al.: Neoadjuvant chemotherapy in muscular invasive bladder cancer: Complications and consequences on cystectomy, Pr Urol 2015; 25: 549-554].
    Coquard R
    Prog Urol; 2015 Dec; 25(16):1171-2. PubMed ID: 26420677
    [No Abstract]   [Full Text] [Related]  

  • 14. Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer.
    Nieuwenhuijzen JA; Bex A; Meinhardt W; Kerst JM; Schornagel JH; VAN Tinteren H; Horenblas S
    J Urol; 2005 Jul; 174(1):80-5. PubMed ID: 15947583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicity and results of MVAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy in advanced urothelial carcinoma.
    Witjes JA; Wullink M; Oosterhof GO; de Mulder P
    Eur Urol; 1997; 31(4):414-9. PubMed ID: 9187900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
    Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
    Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma.
    Soga N; Arima K; Sugimura Y
    Int J Urol; 2008 Sep; 15(9):800-3. PubMed ID: 18651862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumour effects of the angiogenesis inhibitor AGM-1470 on rat urinary bladder tumours induced by N-butyl-N-(4-hydroxybutyl) nitrosamine.
    Osawa S; Terashima Y; Kimura G; Akimoto M
    BJU Int; 1999 Jan; 83(1):123-8. PubMed ID: 10233464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy in the post-MVAC era: the case for adjuvant chemotherapy.
    Lehmann J; Retz M; Stöckle M
    World J Urol; 2002 Aug; 20(3):144-50. PubMed ID: 12196897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of chemotherapeutic effects by recombinant human granulocyte colony-stimulating factor on implanted mouse bladder cancer cells (MBT-2).
    Akaza H; Fukushima H; Koiso K; Aso Y
    Cancer; 1992 Feb; 69(4):997-1002. PubMed ID: 1370920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.